Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma

Phase 1

Terminated

Conditions: Non-Small Cell Lung Cancer
Melanoma

Interventions: Drug: LXH254
Drug: LTT462
Drug: Trametinib
Drug: Ribociclib

First Posted Date: 2016-11-28

Last Posted Date: 2025-04-13

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 241

Registration Number: NCT02974725

Locations: 🇸🇪
Novartis Investigative Site, Stockholm, Sweden
🇺🇸
Uni of TX MD Anderson Cancer Cntr, Houston, Texas, United States
🇺🇸
Sarah Cannon Research Institute Tennessee Oncology, Nashville, Tennessee, United States

and more 4 locations

Study on the Effects of Sacubitril/Valsartan on Physical Activity and Sleep in Heart Failure With Reduced Ejection Fraction Patients.

Phase 4

Completed

Conditions: Heart Failure, Reduced Ejection Fraction

Interventions: Drug: sacubitril/valsartan (LCZ696)
Drug: matching placebo enalapril
Drug: enalapril
Drug: matching placebo sacubitril/valsartan (LCZ696)

First Posted Date: 2016-11-22

Last Posted Date: 2021-10-07

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 140

Registration Number: NCT02970669

Locations: 🇺🇸
Novartis Investigative Site, Tacoma, Washington, United States

A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma

Phase 3

Terminated

Conditions: Melanoma

Interventions: Biological: Spartalizumab
Other: Placebo
Drug: Dabrafenib
Drug: Trametinib

First Posted Date: 2016-11-18

Last Posted Date: 2025-04-29

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 568

Registration Number: NCT02967692

Locations: 🇺🇸
California Cancer Associates for Research and Excellence, Encinitas, California, United States
🇺🇸
UC Irvine Medical Center, Orange, California, United States
🇺🇸
California Pacific Medical Center, San Francisco, California, United States

and more 15 locations

Efficacy and Safety of Ruxolitinib in the Treatment of Anemic Myelofibrosis Patients.

Phase 2

Completed

Conditions: Post-Essential Thrombocythemia Myelofibrosis
Primary Myelofibrosis
Post-Polycythemia Vera-Myelofibrosis

Interventions: Drug: ruxolitinib

First Posted Date: 2016-11-17

Last Posted Date: 2020-04-30

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 51

Registration Number: NCT02966353

Locations: 🇹🇷
Novartis Investigative Site, Kocaeli, Turkey

Safety and Efficacy of VAY736 in Patients With Primary Sjogren's Syndrome (pSS)

Phase 2

Completed

Conditions: Primary Sjogren Syndrome

Interventions: Biological: VAY736
Other: Placebo

First Posted Date: 2016-11-15

Last Posted Date: 2025-01-07

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 190

Registration Number: NCT02962895

Locations: 🇺🇸
Indiana Univ School of Dentistry, Indianapolis, Indiana, United States
🇺🇸
The John Hopkins Jerome L Greene Sjogren, Baltimore, Maryland, United States
🇺🇸
Tufts School of Dental Medicine, Boston, Massachusetts, United States

and more 7 locations

Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment

Phase 3

Active, not recruiting

Conditions: Tuberous Sclerosis Complex

Interventions: Drug: everolimus

First Posted Date: 2016-11-11

Last Posted Date: 2025-05-28

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 206

Registration Number: NCT02962414

Locations: 🇺🇸
TGen APNNA, Phoenix, Arizona, United States
🇺🇸
David Geffen School of Medicine at UCLA, Los Angeles, California, United States
🇺🇸
UCSF Benioff Children s Hospital, Oakland, California, United States

and more 12 locations

Study of SAF312 as an Eye Drop for Treatment of Eye Pain Following Photorefractive Keratectomy (PRK) Surgery

Phase 2

Completed

Conditions: Postoperative Ocular Pain After PRK Surgery

Interventions: Drug: SAF312
Drug: Placebo

First Posted Date: 2016-11-10

Last Posted Date: 2021-10-06

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 40

Registration Number: NCT02961062

Locations: 🇺🇸
Novartis Investigative Site, Norfolk, Virginia, United States

Study of Efficacy, Safety and Tolerability of ACZ885 (Canakinumab) in Pediatric and Young Adult Patients With Sickle Cell Anemia

Phase 2

Completed

Conditions: Sickle Cell Anemia

Interventions: Drug: Placebo
Drug: ACZ885

First Posted Date: 2016-11-10

Last Posted Date: 2021-10-11

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 49

Registration Number: NCT02961218

Locations: 🇬🇧
Novartis Investigative Site, London, United Kingdom

PAtient RegisTry Assessing Effectiveness and Safety of HEart Failure treatmeNt With LCZ696 acrOss CaNada

Completed

Conditions: Heart Failure

Interventions: Drug: sacubitril/valsartan

First Posted Date: 2016-11-06

Last Posted Date: 2021-08-26

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 1009

Registration Number: NCT02957409

Locations: 🇨🇦
Novartis Investigative Site, Quebec, Canada

Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)

Phase 2

Completed

Conditions: Well-differentiated Non-functional NET of Thoracic Origin
Well-differentiated Non-functional NET of Gastrointestinal Origin
Well-differentiated Non-functional NET of Pancreatic Origin
Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma

Interventions: Drug: PDR001

First Posted Date: 2016-11-04

Last Posted Date: 2021-04-12

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 116

Registration Number: NCT02955069

Locations: 🇺🇸
Rocky Mountain Cancer Centers SC-2, Denver, Colorado, United States
🇺🇸
University of TX MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
City of Hope National Medical Center, Duarte, California, United States

and more 5 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy